Vanguard Group’s CNS Pharmaceuticals CNSP Stock Holding History

Vanguard Group’s Portfolio CNSP Stock Details CNSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2	Closed	-$21.1K	–	4419
2024 Q1	$21.1K	Hold	2	–	–	﹤0.01%	4390
2023 Q4	$74.1K	Buy	2 +1	+100%	+$52.3K	﹤0.01%	4339
2023 Q3	$27.1K	Hold	1	–	–	﹤0.01%	4471
2023 Q2	$53K	Buy	+1	New	+$53.7K	﹤0.01%	4451
2022 Q4	–	Sell	-1	Closed	-$81K	–	4533
2022 Q3	$81K	Buy	+1	New	+$214K	﹤0.01%	4508
2022 Q2	–	Hold	0	–	–	–	4530
2022 Q1	–	Sell	-1	Closed	-$422K	–	4569
2021 Q4	$428K	Hold	1	–	–	﹤0.01%	4453
2021 Q3	$908K	Hold	1	–	–	﹤0.01%	4267
2021 Q2	$1.18M	Buy	+1	New	+$1.8M	﹤0.01%	4120
2021 Q1	–	Hold	0	–	–	–	4193
2020 Q4	–	Hold	0	–	–	–	4153

Other funds holding CNSP

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

GRP

Global Retirement Partners San Rafael, California $5.64B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

PMFA

Plante Moran Financial Advisors Southfield, Michigan $1.55B AUM 17.93% 1-Year Est. Return

Vanguard Group's CNSP Position: Q2 2024 in Review

Vanguard Group sold out of CNS Pharmaceuticals (CNSP) in Q2 2024, closing a stake of 2 shares — an estimated $21.1K sold.

Vanguard Group first reported a position in CNSP in Q2 2021 and held it in 8 quarters. The position peaked at $1.18M in Q2 2021. 2 funds tracked by Wall St. Rank hold CNSP as of Q2 2024.

Vanguard Group reported no remaining CNS Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Vanguard Group sold 2 CNS Pharmaceuticals shares in Q2 2024, an estimated $21.1K.
Vanguard Group first reported a position in CNS Pharmaceuticals in Q2 2021 and held it in 8 quarters.
Vanguard Group's CNS Pharmaceuticals position peaked at $1.18M in Q2 2021.
2 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q2 2024.

Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.